Interview 8 Jan 2018 Meet the Swiss CEO Pulling Out All the Stops Against Alzheimer’s Disease …it is still is that way. Even today, when I go to award events I’m sometimes really shocked when no women are even nominated. On the other hand, I’m very… January 8, 2018 - 8 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
In Depth 7 Apr 2025 Will tRNA therapy be the next big thing in genetic disease treatment? …need to prove that their tRNAs will not accidentally be delivered to the wrong target and will not interfere with normal genes, which can potentially trigger adverse events. Having said… April 7, 2025 - 12 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2021 Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain …attacks in high-risk patients, following a phase III clinical trial that showed it reduces the risk of adverse cardiovascular events by 25%. Exactly how Vascepa had such a profound benefit… April 21, 2021 - 5 minutesmins - By Victor Kotsev Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 May 2018 Here Are 10 of the Hottest Biotech Hubs in Europe …delight, with the nearby mountains, forests, lakes, and world famous cultural events and arts.” — Simon Moroney, CEO of MorphoSys Due to world-class universities and research institutes surrounded by an… May 15, 2018 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 25 Jun 2024 Spotlight on Georgia’s biotech industry: Seven companies to know about in 2024 …that prevents viruses from attaching to cells and also inhibits viral replication. The viral capsid is the protein shell that encases and protects the genetic material of a virus. By… June 25, 2024 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2025 Von Willebrand disease: Star Therapeutics, Chugai and Band Therapeutics are breaking new ground …therapy two to three times a week. This high treatment burden prevents some patients from going on chronic prophylaxis,” added Rosenthal. Interim clinical data from the VIVID 2 study presented… January 9, 2025 - 7 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
News and Trends 22 Aug 2022 EpiVario looks to biotech for PTSD treatment …memories of trauma events. The study was conducted at the Perelman School of Medicine at the University of Pennsylvania and was led by EpiVario co-founder Shelley Berger, Daniel S. Och… August 22, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2017 Meet some of the Hottest Startups of 2017! – This article was originally published on 27th September 2017. This is an updated version – Large events, like BIO-Europe offer startup slams, which give entrepreneurs the opportunity to present… October 19, 2017 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 12 Oct 2023 Can immunometabolism-based therapies transform the way cancers and autoimmune diseases are treated? …situation wherein the tumor cells are stripped of oxygen supply – which prevents tumor cells from being killed, and limiting the effect of immunotherapies. This is where immunometabolism drugs could… October 12, 2023 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2023 A gene editing milestone: The FDA approves CASGEVY, the first CRISPR-based therapy …will never get sick.” BCL11A is the specific gene targeted by the CASGEVY CRISPR therapy, as it usually prevents the production of fetal hemoglobin in adults. Therefore, by disrupting this… December 6, 2023 - 6 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 18 Jan 2024 GLP-1 agonists: what’s the hype about? …– Wegovy, in particular – have cut the risk of cardiac-related death in patients with obesity and cardiovascular diseases by 15%, and lowered major adverse cardiovascular events (MACEs) by 20%. … January 18, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Spinoff Biohaven launches with $258M and “incredible pipeline” …ODT (rimegepant), the leading novel calcitonin gene-related peptide (CGRP) receptor antagonist for the treatment of migraine in adults and the first and only therapy that both treats and prevents migraine… October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email